Sanofi-Aventis

Child Organization: Sanofi Pasteur

Sanofi-Aventis, headquartered in Paris, France, is a multinational pharmaceutical company, the world's fourth-largest by prescription sales. Sanofi-Aventis engages in the research and development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but the firm also develops over-the-counter medication. Sanofi-Aventis covers 7 major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world's largest producer of the latter through its subsidiary Sanofi Pasteur). The company is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Source: Wikipedia

Campaign Finance

Information

Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:

  • contributions under $200 are not reported, and so are not included in totals.
  • only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
  • contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
  • corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
  • organization totals include known subsidiaries of the organization.

For more information, please see our campaign finance methodology page. Lobbyist bundling data is described on our lobbyist bundling methodology page.

Latest FEC Data

covers through committee's May 31, 2012 filing.
Download all contributions to Sanofi-Aventis

  • Summary

    overview of the committee's finances
    Total Raised:
    $457,065
    Total Spent:
    $335,773
    Cash on Hand:
    $247,828
    Debts:
    $0

Standardized Donation Information

covers through 2011. may lag behind FEC section above, as donors and industries are identified by hand.

  • Top Recipients

    Employee Color Block
    Individuals
    PAC Color Block
    PAC
    Includes contributions from the organization’s employees, their family members, and its political action committee.

  • Republicans vs. Democrats

    in dollars

  • State vs. Federal

    in dollars

  • Top PAC Recipients

    Employee Color Block
    Individuals
    PAC Color Block
    PAC
    Includes contributions from the organization’s employees, their family members, and its political action committee.
View all campaign finance data for Sanofi-Aventis Sources: OpenSecrets.org FollowTheMoney.org

Lobbying

$3,890,000 Spent
Information

Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.

For more information, please see our lobbying methodology page.

covers through Q3, 2011

Lobbying On Behalf of Sanofi-Aventis

View all lobbying data for Sanofi-Aventis Sources: OpenSecrets.org

Regulations

14 Mentions; 3 Submissions
Information

All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.

Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.

Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.

Regulations and public comments can be downloaded in bulk here.

updated from Regulations.gov on September 27, 2011

The tables show occurrences of "Sanofi-Aventis" in public comments on proposed federal regulations.

  • Documents Submitted by the Organization
    • Submissions
    • Agency
    • Docket
    • Date
    • Toggle 1 FDA Draft Guidance for Industry on Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies; Availability 2011
    • Toggle 1 FDA Medical Device Innovation Initiative; Availability for Comment 2011
    • Toggle 1 FDA Draft Guidance for Industry and FDA Staff on Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets; Availability 2011
  • Mentions in Document Text
    • Mentions
    • Agency
    • Docket
    • Date
    • Toggle 2 FDA Allocate Full Doses of Agalsidase Beta (Fabrazyme®) to U.S. Citizens Under its Consent Decree with Genzyme Corporation 2011
    • Toggle 2 FDA Designate Sanofi-Aventis Drug Product, CLAFORAN® (Cefotazime for Injection) 1g and 2g in ADD-Vantage® Vial for Purposes of Submitting an Abbreviated New Drug Application (ANDA) 2011
    • Toggle 1 FDA Agency Information Collection Activities; Proposed Collection; Comment Request; Examination of Online Direct-to-Consumer Prescription Drug Promotion 2011
    • Toggle 1 FDA Draft Guidance for Industry and FDA Staff on Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets; Availability 2011
    • Toggle 1 FDA Medical Device Innovation Initiative; Availability for Comment 2011
    • Toggle 1 HHS HIPAA Privacy Rule Accounting of Disclosures under the Health Information Technology for Economic and Clinical Health Act 2011
    • Toggle 1 FDA Abbott Vascular, Premarket Approval of RX Herculink Elite Renal Stent System P110001, Approved 7/20/11 2011
    • Toggle 1 FDA To Declare that Pentazocinne Hydrochloride and Acetaminophen Tablets, 12.5 mg/325 mg and 25 mg/325 mg are Suitable for Submission as an Abbreviated New Drug Application (ANDA) 2011
    • Toggle 1 FDA Establish Comprehensive, Clear and Binding Regulations to Guide The Industry Relating to New Uses of Marketed Drugs and Medical Devices 2011
    • Toggle 1 FDA Abbott Vascular, Premarket Approval of XIENCE nano™ Everolimus-Eluting Coronary Stent System and PROMUS™ Everolimus-Eluting Coronary Stent System, P070015/S054; Approved 5/24/11 2011

Contractor Misconduct

3 Instances
Information

This information is collected by the Project On Government Oversight from press releases, court documents, news reports and other public records. It is not meant to be an exhaustive account of all instances of federal contractor misconduct.

More information on each instance, including primary source documents, is available on POGO's site by clicking on the instance description. More information on POGO's methodology is available here.

covers through POGO's March 3, 2012 release
Misconduct Type Hired By Incident Year Disposition Penalty
Antitrust None Failure to Report Ambien Patent Agreements 2011 Investigative Finding $0
Health None FDA Inspection of Bridgewater, NJ Facility 2011 Investigative Finding $0
Health None FDA Inspection of Frankfurt, Germany Facility 2011 Investigative Finding $0
View all contractor misconduct data for Sanofi-Aventis Sources: Federal Contractor Misconduct Database from POGO